Ignite Creation Date:
2024-05-06 @ 1:32 AM
Last Modification Date:
2024-10-26 @ 11:06 AM
Study NCT ID:
NCT01839357
Status:
COMPLETED
Last Update Posted:
2016-07-25
First Post:
2013-04-22
Brief Title:
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left AtrialLeft Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
An Open-label International Multicenter Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban BAY 59-7939 for the Treatment of Left AtrialLeft Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
X-TRA
Brief Summary:
A study for subjects with atrial fibrillation AF or atrial flutter who are diagnosed with left atrial LA or left atrial appendage LAA thrombus The study will assign subjects to rivaroxaban for treatment of thrombi The study will measure thrombus outcomes based on echo image and common clinical outcomes such as bleeding and stroke or thromboembolism
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-001062-15 | EUDRACT_NUMBER | None | None |